Nanoparticle-aptamer bioconjugates: A new approach for targeting prostate cancer cells

Cancer Research

Volumn 64, Issue 21, 2004, Pages 7668-7672

  Farokhzad, Omid C ^a,b   Jon, Sangyong ^c   Khademhosseini, Ali ^b   Tran, Thanh Nga T ^b   LaVan, David A ^b   Langer, Robert ^b,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c Gwangju Institute of Science and Technology (GIST)   (South Korea)

^d Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRAN; MACROGOL; NANOPARTICLE; RHODAMINE;

ACINAR CELL; ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG TARGETING; EPITHELIUM CELL; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE EPITHELIUM; SURFACE PROPERTY;

ANTIGENS, SURFACE; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; LACTIC ACID; MALE; OLIGONUCLEOTIDES; POLYETHYLENE GLYCOLS; POLYMERS; PROSTATIC NEOPLASMS;

EID: 7444223607     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2550     Document Type: Article

References (20)

1. Langer R. Drug delivery and targeting. Nature (Lond.) 1998;392:5-10.
2. Langer R. Drug delivery. Drugs on target. Science (Wash. DC) 2001;293:58-9.
3. Weiner LM, Adams GP. New approaches to antibody therapy. Oncogene 2000;19:6144-51.
4. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature (Lond.) 1990;346:818-22.
5. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science (Wash. DC) 1990;249:505-10.
6. Ishida S, Usui T, Yamashiro K, et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 2003;198:483-9.
7. Brody EN, Gold L. Aptamers as therapeutic and diagnostic agents. J Biotechnol 2000;74:5-13.
8. Vinores SA. Technology evaluation: pegaptanib, Eyetech/Pfizer. Curr Opin Mol Ther 2003;5:673-9.
9. Lupold SE, Hicke BJ, Lin Y, Coffey DS. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the PSMA. Cancer Res 2002;62:4029-33.
10. Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer (Phila.) 1998;83:2259-69.
11. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res 1994;54:1807-11.
12. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA - Cancer J Clin 2004;54:8-29.
13. Leach F. Targeting prostate-specific membrane antigen in cancer therapy: can molecular medicine be brought to the surface? Cancer Biol Ther 2004;3:
14. Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol 2003;30:667-76.
15. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science (Wash. DC) 1994;263:1600-3.
16. Fenske DB, MacLachlan I, Cullis PR. Stabilized plasmid-lipid particles: a systemic gene therapy vector. Methods Enzymol 2002;346:36-71.
17. Iinuma H, Maruyama K, Okinaga K, et al. Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int J Cancer 2002;99:130-7.
18. Liu H, Rajasekaran AK, Moy P, et al. Constitutive and antibody-induced internalization of prostate- specific membrane antigen. Cancer Res 1998;58:4055-60.
19. Willis MC, Collins BD, Zhang T, et al. Liposome-anchored vascular endothelial growth factor aptamers. Bioconjug Chem 1998;9:573-82.
20. Hicke BJ, Stephens AW. Escort aptamers: a delivery service for diagnosis and therapy. J Clin Investig 2000;106:923-8.